Organ-selective switching of 3-methylindole toxicity by glutathione depletion

Nephrotoxicity and covalent binding of 1,1-dichloroethylene in buthionine sulphoximine-treated mice

Autoradiography of mice injected i.p. with 14C-labelled 1,1-dichloroethylene (vinylidene chloride, VDC) in C57B1/6 mice revealed a selective covalent binding of radioactivity in the proximal tubules, in the midzonal parts of the liver lobules and in the mucosa of the upper and lower respiratory tract. Since VDC is a renal carcinogen in male mice the effects of compounds modulating biotransformation and glutathione (GSH) levels on the renal covalent binding were examined following a single i.p. dose of 14C-VDC. Most pretreatments did not influence the level of binding but treatment with buthionine sulphoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and glutathione (GSH)-depleting agent, increased the renal covalent binding of VDC three-fold. Histopathological examination of kidneys in BSO-pretreated male mice given single i.p. injections of subtoxic doses of VDC (25 and 50 mg/kg) showed necrosis in the proximal tubules (S1 and S2 segments) 24 h following administration. In mice given VDC only, no significant lesions in the kidneys were observed. The severe renal toxicity of VDC in BSO-pretreated mice is suggested to be related to metabolic activation of VDC in the proximal tubules, resulting in further GSH depletion and covalent binding.

Effects of glutathione-modulating agents on the covalent binding and toxicity of dichlobenil in the mouse olfactory mucosa

Twenty-four hours following injection of a single dose of the herbicide dichlobenil (2,6-dichlorobenzonitrile) in C57Bl/6 mice a steep dose-response curve for the histopathological toxicity in the olfactory mucosa was observed. Four hours following injection of a toxic dose of [ring-14C]dichlobenil (12 mg/kg) the covalent binding in the olfactory mucosa was 26 times higher than that in the liver. A dose-dependent decrease of nonprotein sulfhydryls (mainly glutathione, GSH) in the olfactory mucosa was observed 2.5 hr following injection of dichlobenil (6, 12, 25 mg/kg). The synthetic GSH precursor N-acetyl-L-cysteine decreased both the dichlobenil-induced toxicity and the covalent binding, whereas N-acetyl-D-cysteine had no effect. No protective effects of the cyanide antidotes nitrite, thiosulfate, or superoxide dismutase on the dichlobenil-induced toxicity were observed. In mice given the GSH-depleting agent phorone and a subtoxic dose of dichlobenil (6 mg/kg), an extensive toxicity and an increased covalent binding in the olfactory mucosa were demonstrated. Autoradiography showed no change in the distribution of covalent [14C]dichlobenil binding to nontarget tissues of phorone-treated mice. In conclusion, the results demonstrate a relationship between the degrees of covalent binding, GSH depletion, and toxicity of dichlobenil in the olfactory mucosa. Hence, the level of GSH appears to be of importance for the dichlobenil-induced toxicity in the olfactory mucosa.

The effect of partial hepatectomy on the metabolism, distribution, and nephrotoxicity of para-methylthiobenzamide in the rat

Para-Methylthiobenzamide (PMTB) produces injury to the liver and kidney. Toxicity is mediated via its biotransformation to a reactive S,S-dioxide metabolite. The objective of this study was to examine the role of hepatic metabolism in the production of PMTB-induced renal toxicity. Renal injury was assessed in partially hepatectomized and sham-operated rats and the effect of this procedure on the distribution and metabolism of PMTB was examined. The in vitro oxidation of PMTB and [14C]thiobenzamide by rat kidney microsomes was also examined. Plasma urea levels and renal cortical slice uptake of organic ions were used to monitor renal function. Partial hepatectomy alone did not alter renal function nor raise blood urea nitrogen levels. Nephrotoxicity resulted when a nonnephrotoxic dose of PMTB (1.2 mmol/kg) was given to partially hepatectomized rats. An HPLC method was used for measurement of PMTB and its metabolites para-methylthiobenzamide S-oxide (PMTBSO) and para-methylbenzamide (PMBA) in plasma and kidney. Hepatectomy delayed the removal of this dose of PMTB from plasma and allowed greater concentrations of PMTB and PMTBSO to accumulate in plasma and kidney at 6 and 15 hr. The level of PMBA was similar in both groups at 6 hr, but was increased in plasma and kidney of the hepatectomized group at 15 hr. Kidney microsomes rapidly converted PMTB to PMTBSO and small amounts of PMBA. [14C]TB was oxidized by microsomes to thiobenzamide S-oxide, benzamide, and covalently bound metabolites. The results indicate that partial hepatectomy lowered the threshold for the expression of nephrotoxicity by PMTB. This procedure is associated with an increased renal accumulation of PMTB and PMTBSO, which are both sequentially transformed to the toxic metabolite.

Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s

Twelve human cytochrome P450s and one mouse P450 were produced in HepG2 cells using vaccinia virus cDNA expression and analyzed for their ability to bioactivate the pneumotoxin, 3-methylindole (3MI), to an electrophilic metabolite(s) which alkylated cellular macromolecules. Cell lysates containing CYP2C8, CYP3A4, CYP2A6 and CYP2F1 metabolized 3MI to an intermediate(s) that became covalently bound to lysate material. A control lysate produced from cells which had been infected with a wild-type vaccinia virus was not able to bioactivate 3MI. The mouse 1A2 enzyme metabolized 3MI at a rate of 75.4 pmol/mg protein/minute, while the rate of metabolism in the lysate containing the human 1A2 P450 enzyme was not different from that in the control lysate. Therefore, the catalytic capabilities of orthologous P450 enzymes to activate 3MI cannot be extrapolated among different species. These results indicate that human P450s are capable of bioactivating 3MI to a metabolite which binds to cellular macromolecules suggesting that this compound may be toxic to humans.

Tissue-specific changes in glutathione and cysteine after buthionine sulfoximine treatment of rats and the potential for artifacts in thiol levels resulting from tissue preparation

L-Buthionine-S,R-sulfoximine (BSO), a potent inhibitor of gamma-glutamylcysteine synthetase, is commonly used as an experimental tool for the specific depletion of glutathione. Since cysteine is a key precursor for glutathione biosynthesis, we investigated the possibility that BSO might also affect the free cysteine pool in rat liver and kidney tissues in vivo. Male CD(SD)BR rats (150-200 g) were injected ip with various doses of BSO (0.25-4.0 mmol/kg), and glutathione and cysteine were measured in liver and kidney using HPLC with electrochemical detection and/or spectroscopic techniques. No hepatotoxicity or nephrotoxicity was observed at the highest BSO dose (4.0 mmol/kg) used. BSO caused the expected decreases of hepatic and renal glutathione at all doses, although glutathione depletion was more rapid, was achieved at a lower BSO dose, and was more sustained in kidney than in liver. Hepatic cysteine levels nearly doubled 20 min after BSO treatment (1.0 mmol/kg, ip), but were not significantly different from control at later time points. In contrast, renal cysteine was significantly depleted from 20 min to 25 hr postinjection with a time course closely paralleling that of renal glutathione depletion. These changes are discussed in the context of models for inter- and intraorgan transport of glutathione and cysteine. We also provide evidence that an artifact, most likely the gamma-glutamyltranspeptidase (GGT)-initiated breakdown of glutathione, leads to a rapid postmortem increase of cysteine levels in liver and particularly in kidney of rats. Simultaneous decreases in GSH levels can be demonstrated in kidney. This artifact needs to be minimized in toxicological studies of glutathione and cysteine in kidney and other GGT-rich organs, as the measured levels of these thiols may not reflect the true concentrations occurring in vivo.

Bioactivation of 3-methylindole by isolated rabbit lung cells

3-Methylindole (3MI) is a pneumotoxin that causes selective lung lesions indicative of Clara cell and alveolar epithelial cell damage in ruminants and rodents. The present study examined the cytotoxicity of 3MI to isolated rabbit Clara cells, type II alveolar epithelial cells, and alveolar macrophages. 3MI produced a dose-dependent cytotoxicity to Clara cells detectable within 1 hr of incubation at 37 degrees C which reached a maximum at 3 hr. Concentrations of 0.25 and 0.5 mM 3MI were cytotoxic to Clara cells, while type II and alveolar macrophages required 1 mM 3MI before cytotoxicity was observed. The cytochrome P450 suicide substrate inhibitor, 1-aminobenzotriazole, inhibited 3MI-induced cytotoxicity in Clara cells, type II cells, and alveolar macrophages. These observations were consistent with a cytochrome P450-mediated bioactivation of 3MI to a toxic intermediate. Studies with a trideuteromethyl analog of 3MI demonstrated a much reduced cytotoxicity to Clara cells as well as to type II cells, and macrophages. The deuterium isotope effect suggested that C-H bond breakage at the 3-methyl group is a requisite oxidative transformation in the bioactivation of 3MI to a selective lung cell cytotoxin. The selectivity of cellular cytotoxicity is probably associated with higher rates of bioactivation by Clara cell cytochrome P450 monooxygenases compared to those of type II cells and macrophages. These studies demonstrate that 3MI is bioactivated in isolated pulmonary cells without the intervention of other organs and that bioactivation requires functional cytochrome P450 enzymes.